Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: Empirical and therapeutic significance

Clinical Cancer Research

Volumn 16, Issue 8, 2010, Pages 2266-2274

  Williams, Michelle D ^a   Roberts, Dianna B ^a   Kies, Merrill S ^a   Mao, Li ^a   Weber, Randal S ^a   El Naggar, Adel K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CHROMOSOME 17; CHROMOSOME 7; CONTROLLED STUDY; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; TISSUE MICROARRAY;

CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 7; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; PLOIDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77951004343     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0238     Document Type: Article

References (49)

1. Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 1994;78:64-73.
2. Kleinsasser O, Klein HJ, Hubner G. [Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 1968;192:100-105
3. Barnes L, Rao U, Contis L, Krause J, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol 1994;78:74-80.
4. Etges A, Pinto DS, Jr., Kowalski LP, Soares FA, Araujo VC. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 2003;56:914-918 (Pubitemid 37533233)
5. Williams MD, Roberts D, Blumenschein GR, Jr., et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 2007;31:1645-1652 (Pubitemid 350287562)
6. El-Naggar AK, Callender D, Coombes MM, Hurr K, Luna MA, Batsakis JG. Molecular genetic alterations in carcinoma expleomorphic adenoma: a putative progression model? Genes Chromosomes Cancer 2000;27:162-168
7. Cornolti G, Ungari M, Morassi ML, et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg 2007;133:1031-1036 (Pubitemid 47607587)
8. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005;103:2526-2533 (Pubitemid 40800531)
9. Gupta R, Dastane AM, Forozan F, et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol 2009; 22:128-133
10. Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 2006;11:3-11. (Pubitemid 44309185)
11. Fuqua SA, Schiff R, Parra I, et al. Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003;63:2434-2439 (Pubitemid 36605180)
12. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112:S53-67.
13. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
14. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145 (Pubitemid 350003059)
15. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-69
16. Ellis IO, Bartlett J, Dowsett M, et al. Best practice no 176: updated recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57:233-237
17. O'Malley FP, Parkes R, Latta E, et al. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 2001;115:504-511 (Pubitemid 32275941)
18. Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 2005;124:273-281 (Pubitemid 41060140)
19. Konigshoff M, Wilhelm J, Bohle RM, Pingoud A, Hahn M. HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem 2003;49:219-229 (Pubitemid 36143442)
20. Bofin AM, Ytterhus B, Martin C, O'Leary JJ, Hagmar BM. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004;122:110-119 (Pubitemid 38849881)
21. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-2139 (Pubitemid 38637993)
22. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500 (Pubitemid 38720929)
23. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311 (Pubitemid 39209661)
24. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807 (Pubitemid 46606235)
25. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-286 (Pubitemid 40590264)
26. Morrison LE, Jacobson KK, Friedman M, Schroeder JW, Coon JS. Aberrant EGFR and chromosome 7 associate with outcome in laryngeal cancer. Laryngoscope 2005;115:1212-1218 (Pubitemid 40962358)
27. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25:2164-2170 (Pubitemid 46954638)
28. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24: 4170-4176 (Pubitemid 46622295)
29. Fan CY, Melhem MF, Hosal AS, Grandis JR, Barnes EL. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor α in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:1075-1079 (Pubitemid 32848184)
30. Barnes EL, Evenson JW, Reichart P, Sidransky D. Pathology and genetics head and neck tumours. Lyon, France: IARC Press; 2003.
31. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655 (Pubitemid 40812628)
32. Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008;53:567-577
33. Sheikh MS, Carrier F, Johnson AC, Ogdon SE, Fornace AJ, Jr. Identification of an additional p53-responsive site in the human epidermal growth factor receptor gene promotor. Oncogene 1997; 15:1095-1101
34. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007;19:2013-2023 (Pubitemid 47353811)
35. Shupnik MA. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004;23:7979-7989
36. Dancey JE. Predictive factors for epidermal growth factor receptor inhibitors - the bull's-eye hits the arrow. Cancer Cell 2004;5:411-415
37. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ("Iressa", ZD1839) in non-small-cell lung cancer. Br J Cancer 2004;91:208-212 (Pubitemid 39037060)
38. Felip E, Rojo F, Reck M, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008;14:3867-3874
39. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005;23:5007-5018 (Pubitemid 46224007)
40. Wong TW, Lee FY, Yu C, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006;12:6186-6193 (Pubitemid 44703785)
41. Skalova A, Starek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2003;42:348-356 (Pubitemid 36459812)
42. Dagrada GP, Negri T, Tamborini E, Pierotti MA, Pilotti S. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2004;44:301-302 (Pubitemid 38406627)
43. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer 1993;72:1503-1512
44. Hellquist HB, Karlsson MG, Nilsson C. Salivary duct carcinoma-a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J Pathol 1994;172:35-44. (Pubitemid 24074999)
45. Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod Pathol 2008;21:363-368 (Pubitemid 351441033)
46. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005;93:3-11. (Pubitemid 41355986)
47. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6:240-246 (Pubitemid 47050800)
48. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003;39:724-727 (Pubitemid 36930120)
49. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004;10:944-946 (Pubitemid 38198894)